Cure8 research brief
This NIH-funded project identifies probiotic metabolic pathways that protect gut barrier integrity in a diet-dependent way, which could explain mixed clinical trial results and point to biomarkers to select patients likely to benefit.
Researchers (microbiome, metabolism), translational clinicians, and IBD-interested patients/caregivers wanting mechanistic insight into probiotics.
NIH-funded project from Rutgers is studying how the probiotic Lactobacillus rhamnosus GG protects the gut barrier in a diet-dependent way.
The team identified two metabolic pathways the probiotic uses: production of nicotinamide-related isomers that can fuel host NAD synthesis, and degradation/removal of a serum arginine metabolite that impairs barrier function.
The work uses mice, fruit flies, human cells and organoids and will employ stable isotope tracing, genetics, and disease models to map mechanisms and cell types.
The proposal links these probiotic-driven metabolites to intestinal stem cell renewal and epithelial healing and notes that levels of these metabolites are altered in people with IBD, suggesting they could serve as biomarkers to guide probiotic use.
This is mechanistic, preclinical/translational research (funded project record), not a completed clinical trial. It aims to define which patients and dietary conditions might benefit from probiotic interventions rather than establish treatment recommendations.
Funded project record describing planned and ongoing mechanistic research across model systems; not a report of completed clinical trial findings.
Review the original publication for the complete reporting, methods, and context.
Funding disclosed by the source: National Center for Complementary and Integrative Health - R01AT013333 - $642,063
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The review highlights how microbial metabolites, epigenetic regulation, and mitochondrial metabolism interact to shape inflammation and barrier function in IBD. Understanding these links could help identify new...
The study suggests a plant-derived AHR-activating mechanism that reduced inflammation and repaired the intestinal barrier in preclinical ulcerative colitis models, a pathway that could be relevant to future therapies or...
The study maps how two ginger preparations differently affect metabolism and the gut microbiome in a mouse model of ulcerative colitis, which could inform more targeted use of ginger-derived treatments if findings are...
